Human herpesvirus 8 (HHV-8) interleukin-6 (vIL-6) promotes cell proliferation and survival and is proangiogenic, implicating it as a contributor to virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease. Although predominantly lytically expressed, vIL-6 is also produced at low, functional levels during latency in PEL cells. Unlike other IL-6 cytokines, vIL-6 is secreted very inefficiently and localizes in the endoplasmic reticulum (ER). ER-localized vIL-6 supports PEL cell proliferation and survival, mediated in part through its interaction with the largely uncharacterized ERresident protein vitamin K epoxide reductase complex subunit 1 variant 2 (VKORC1v2). Here, we report that the ER-transiting and functionally mitogenic secreted proenzyme (pCatD) form of cathepsin D (mature CatD), a proapoptotic lysosomal aspartate protease, is an interaction partner of VKORC1v2 and that vIL-6 promotes this interaction. Depletion of vIL-6 in PEL cells increased levels of the catalytically active, proteolytically cleaved form of CatD, corresponding with decreased PEL cell viability. Ectopic expression of CatD in PEL cells induced apoptosis, suggesting that CatD suppression by vIL-6 is biologically significant. In the context of high-density culture or reactivation of HHV-8 lytic replication in PEL cells, CatD depletion substantially reduced stress-induced apoptosis and increased virus production. In contrast, CatD overexpression, vIL-6 depletion, and peptidemediated disruption of vIL-6 -VKORC1v2 interaction inhibited replication and cell survival. Combined, our data identify pCatD as an interaction partner of VKORC1v2, demonstrate a role of vIL-6 in CatD suppression via VKORC1v2 in PEL cells, and identify a biologically significant mechanism of vIL-6 prosurvival and proreplication activities via VKORC1v2.
S
everal proteins encoded by human herpesvirus 8 (HHV-8) have been speculated to be involved in HHV-8-associated Kaposi's sarcoma (KS), an endothelial tumor, and the B cell malignancies primary effusion lymphoma (PEL) and multicentric Castleman's disease (1) (2) (3) (4) . Latent and lytic viral products are believed to contribute to disease development via autocrine and paracrine mechanisms, respectively. Viral interleukin-6 (vIL-6) is a lytically produced cytokine capable of mediating paracrine signaling to promote cell growth and survival in addition to proinflammatory and angiogenic responses that are relevant to HHV-8-associated disease (5) . However, the viral cytokine is also a bona fide latency product in the context of PEL cells and is capable of supporting growth and viability of these cells via autocrine mechanisms (6) . PEL-produced and -secreted vIL-6, along with cellular IL-10, has been reported to be an important factor for PEL cell growth (7) . However, unlike cellular IL-6 proteins, vIL-6 is secreted inefficiently and intracellularly is retained almost exclusively within the endoplasmic reticulum (ER). vIL-6 is able to signal via the IL-6 signal transducer, gp130, from this compartment. This raises the possibility that the viral cytokine can contribute directly, via an autocrine mechanism independent of secreted vIL-6, to PEL pathogenesis (6, 8) . If expressed in the context of normal (nonmalignant) latency in B cells or other cell types, vIL-6 could contribute to latency maintenance through promotion of cell proliferation and survival to sustain latently infected reservoirs within the host.
While it is likely that vIL-6 can, at least in some circumstances, contribute to latent cell proliferation and viability, its role during lytic replication, when it is maximally expressed, remains unknown. The only published study relating to this issue was that of Chen and Lagunoff (9) . These investigators utilized a vIL-6-null HHV-8 mutant in BJAB cell-based replication experiments to investigate the potential influence of vIL-6 on productive replication efficiency. These experiments showed clearly that in this cell type, vIL-6 did not detectably affect HHV-8 productive replication. However, whether vIL-6 regulates replication in other cell types and/or does so in ways that can be revealed only in more physiological settings remained open possibilities.
The progrowth and antiapoptotic activities of vIL-6 in PEL cells are mediated in part through its interaction with a novel protein derived from a splice variant of the transcript encoding the warfarin target vitamin K epoxide reductase complex subunit 1 (VKORC1) (10, 11) . The variant protein, VKORC1 variant 2 (VKORC1v2), localizes to endoplasmic reticulum (ER) membranes and is uniquely orientated for vIL-6 interaction via a transmembrane-proximal motif (vIL-6-binding domain, vBD) located in the ER-lumenal C tail. Both VKORC1v2 and its interaction with vIL-6 are important for sustained growth and viability of PEL cells, as determined from depletion, rescue, and vIL-6 -VKORC1v2 interaction-disruption experiments utilizing lentivi-ral vector-delivered short hairpin RNAs (shRNAs), complementing wild-type and vBD-deleted VKORC1v2 proteins, and vBD peptide overexpression, respectively (10) . Thus, VKORC1v2 appears to be a biologically important target of vIL-6, but the mechanism of vIL-6 activity through this protein was not previously addressed.
Here, we investigated the mechanism by which vIL-6 contributes to PEL cell growth and survival via VKORC1v2. Using yeast two-hybrid screening and subsequent verification in transfected cells, we identified interaction between the ER-lumenal C-tail portion of VKORC1v2 and cathepsin D (CatD), the full-length proenzyme (pCatD) form of which transits through the ER and binds VKORC1v2. We found that this interaction was enhanced by vIL-6 cointeraction with VKORC1v2 and that vIL-6 suppressed the expression of cleaved (enzymatically active) CatD in addition to pCatD. Expression of CatD was correlated with reduced cell viability and HHV-8 replication efficiency upon lytic reactivation in PEL cells. Our data identify a new interaction partner of VKORC1v2 and a mechanism of ER-localized vIL-6 activity via VKORC1v2.
MATERIALS AND METHODS
Yeast two-hybrid screening. Sequences encoding the ER-lumenal region of VKORC1v2 were cloned between the EcoRI and PstI sites of the bait vector pGBKT7 (catalog number 630303; Clontech), which expresses amino acids 1 to 147 of Gal4 [Gal4(1-147)], and the vector was used to transform Saccharomyces cerevisiae strain AH109. Transformed yeast cells were used to screen yeast cells that were pretransformed with a HeLaderived cDNA library (catalog number 638862; Clontech). Mating, identification, confirmation of positive clones, and recovery of the prey plasmid were performed according to the manufacturer's protocols. Positive clones were sequenced for identification of the expressed cDNAs.
Cell culture and gene transduction. JSC-1 and BCBL-1 primary effusion lymphoma (PEL) cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). Telomerase-immortalized microvascular endothelial (TIME) cells were grown in EGM-2 medium (Lonza) containing 5% FBS and cytokine supplements. HEK293T cell monolayers were grown in Dulbecco's modified Eagle's medium containing 10% FBS. For transfection of HEK293T cells, cultures were passaged 12 to 24 h prior to transfection to produce 60% confluent monolayers; calcium phosphate-DNA coprecipitates, generated by mixing CaCl 2 and HEPES-buffered saline (using standard procedures), were added to cell monolayers. In general, 0.25 to 1.0 g of protein expression vectors and a total of 2 g of DNA were used to transfect approximately 2.5 ϫ 10 5 cells in six-well plates. For lentiviral vector-mediated gene transduction into PEL cells, 1 ϫ 10 6 cells were mixed with lentivirus in the presence of 5 mg/ml Polybrene and incubated at 37°C for 5 h. The inoculum was then replaced with fresh medium, and cultures were allowed to rest for 2 days prior to being monitored for growth and apoptosis.
Measurements of cell growth and apoptosis. For cell growth assays, 100-l aliquots of cultures (10 5 cells/ml) were seeded per well in a 96-well tissue culture plate. At various times, samples were taken, and trypan blue-excluding (viable) cells were counted using a hemocytometer to determine cell densities and to generate growth curves. To measure apoptosis, PEL cells were washed once with phosphate-buffered saline (PBS) containing 0.1% sucrose, suspended in 1 ml of annexin V binding buffer (10 mM HEPES [pH 7.4], 140 mM NaCl, and 2.5 mM CaCl 2 ) supplemented with 1 l of annexin V-Cy3 stock solution (catalog number 1002-200; BioVision), and incubated in the dark at room temperature for 5 min. After two washes in binding buffer, cells were fixed with 4% paraformaldehyde (15 min at room temperature in the dark), permeabilized using 0.25% Triton X-100, and stained with 0.1% 4=,6=-diamidino-2-phenylindole (DAPI) for 1 min. After being washed briefly in PBS, cells were transferred to a glass slide and visualized by UV microscopy. Several random fields were viewed to calculate average percentages of annexin V-Cy3-staining cells (apoptotic; Cy3 positive [Cy3 ϩ ]) in the total cell population (DAPI-positive [DAPI ϩ ] cells). HHV-8 replication assays. For HHV-8 productive replication assays, 5 ϫ 10 5 CatD expression cassette-or CatD shRNA-transduced PEL cells or appropriate controls were mixed with 20 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA) and 0.5 M sodium butyrate (NaB). After incubation for 6 h, the cells were collected and cultured with 1 ml of fresh RPMI 1640 medium containing 10% fetal calf serum and 20 ng/ml TPA. Virus-containing medium was collected after 3 and 5 days for JSC-1 and BCBL-1 cells, respectively (reflecting the respective times required for completion of replication). For infectious virus titration, 400-l samples of culture medium derived from TPA-induced cultures were applied to naive TIME cultures in 12-well plates, and these were centrifuged for 1 h at 400 ϫ g and then incubated at 37°C for 1 h prior to the addition of fresh medium. After 2 days, virus titers were measured by immunofluorescence staining for HHV-8 latency-associated nuclear antigen (LANA); LANAspecific antibody was obtained from Advanced Biotechnologies Inc. (catalog number 13-210-100).
Plasmids, lentiviral vectors, and RT-PCR primers. pSG5-based eukaryotic expression vectors for vIL-6, KDEL motif-tagged green fluorescent protein (GFP), and chitin-binding domain (CBD) fusions of VKORC1 variants 1 and 2 have been described previously (6, 10) . A vIL-6-GFP-KDEL expression vector was generated by ligating plasmid-derived vIL-6 open reading frame (ORF) sequences to PCR-derived and restriction-cleaved GFP-KDEL coding sequences to form a template for PCR amplification of the vIL-6-GFP-KDEL fusion ORF using appropriate restriction site-containing primers; the digested PCR product was cloned between the EcoRI and BglII sites of pSG5. A vector expressing vIL-6 fused to a StrepII tag was made by cloning PCR-derived vIL-6 ORF sequences linked in frame to StrepII tag sequences (contained in the 3= PCR primer) between the HindIII and XhoI sites of vector pcDNA3.1(ϩ) (Invitrogen). A newly identified splice variant of VKORC1, VKORC1v3, was amplified by reverse transcription-PCR (RT-PCR) for cloning into pSG5.CBD (12) between the EcoRI and BamHI sites in frame with CBD coding sequences. The ER-lumenal C tail of VKORC1v2 and deleted derivatives thereof were cloned between the EcoRI and PstI sites of the Gal4(1-147) yeast expression vector pGBKT7 (Clontech). pGBKT7 plasmid specifying vIL-6 was described previously (10) , and p53-encoding pGBKT7 was obtained from Clontech. The cathepsin D (CatD) ORF was derived by RT-PCR of BCBL-1 RNA using appropriate 5= and 3= primers containing terminal EcoRI and BglII restriction sites and was cloned between the EcoRI and BamHI sites of the Flag epitope-containing pSG5-based vector pJH492 (provided by Diane Hayward) to enable expression of Flag-tagged CatD in transfected cells. For cotranslational expression of native CatD and mVenus (control for transfection and expression) in transfected cells, the two coding sequences were linked via the "self-cleaving" (ribosome-skip-inducing) peptide 2A (P2A) from porcine teschovirus (13) . Sense and antisense oligonucleotides encoding P2A were annealed and ligated in frame to the 3= end of mVenus ORF sequences through a BamHI site; a contiguous mVenus-P2A-CatD fusion ORF was then constructed by overlapping PCR and cloned between AgeI and MluI sites of a pGIPZ (ThermoScientific)-derived lentiviral vector in which the GFP-IRES-Puro (where IRES is internal ribosome entry site and Puro is puromycin) region of pGIPZ was replaced by red fluorescent protein (RFP) coding sequences. A similar method was used for generation of RFP-P2A-vIL-6 coding sequences (for transduction of PEL cells). For expression of native CatD in PEL cells, PCR-derived CatD ORF sequences were cloned between the BamHI and XhoI sites of the lentiviral vector plasmid pDuet011 (14) . pYNC352-based lentiviral vector plasmids specifying nonsilencing (NS; control) and vIL-6 mRNA-directed shRNAs have been reported previously by this laboratory (6) ; an equivalent vector encoding a CatD-specific shRNA was constructed by cloning synthetic double-stranded oligonucleotide sequences (containing shRNA target sequence GCACCTACGTGA AGAATGG) between the BamHI and MluI sites of pYNC352. A pYNC419-based lentiviral vector expressing an shRNA-resistant form of vIL-6 was reported previously (6) . ER-directed (N-terminal signal peptide-containing) and ER-retained (C-terminal KDEL-motif-tagged) GFP or GFP fused with the vIL-6-binding domain (vBD) of VKORC1v2 were generated in the lentiviral vector pDUET011 (14) , as previously described (10) . Primers used for RT-PCR detection of vIL-6, CatD, VKORC1, and glyceraldehyde-3-phosphate dehydrogenase (GADPH) transcripts were as follows: vIL-6, GGACGCCCCCGAGTTTGA and TCGTTGATGGCT GGTAGTTTC (ORF nucleotide positions 75 to 92 and 236 to 216, respectively); CatD, CTACCCCCGCATCTCCGTCAACA and GCAGCTCGCG CACCTCATCC (positions 606 to 628 and 934 to 915); VKORC1, GCTC GCTCTTTGCCTGACG and ACCTTCCGGAAACTGAGCCACATC (variant 2 ORF positions 36 to 54 and 348 to 325); GADPH, TTGCCAT CAATGACCCCTTCA and CGCCCCACTTGATTTTGGA (positions 290 to 310 and 463 to 445 of NM_001256799).
Lentivirus production. Plasmid lentiviral vectors (12 g) expressing shRNAs or proteins were cotransfected with a Gag/Pol-expressing plasmid (9 g) and vesicular stomatitis virus G protein-encoding plasmid (3 g) into 60% confluent HEK293T monolayers in 75-cm 2 culture flasks. Two days posttransfection, virus was isolated and concentrated from medium by centrifugation at 25,000 rpm in an SW28 rotor for 2 h at 4°C. Virus pellets were resuspended in 1 ml (pDUET011-derived virus) or 5 to 10 ml (pYNC352-derived virus) of RPMI 1640 medium supplemented with 10% FBS. Infectious titers of lentivirus stock preparations were established using GFP-based assays in inoculated PEL cultures prior to the experimental use of the viral vectors in these cells.
Coprecipitations and immunoblotting. Tagged proteins used in coprecipitation assays comprised CBD or StrepII fusions of VKORC1 variants or vIL-6 expressed with partner proteins in plasmid vector-transfected HEK293T cells. Transfected cells were lysed in buffer containing 100 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, and 0.1% NP-40, and nuclei and cell debris were sedimented by centrifugation at 10,000 ϫ g. For precipitation of StrepII-tagged vIL-6, cleared lysates were incubated with StrepTactin beads (catalog number 30002; Qiagen) at 4°C overnight. Beads were pelleted and resuspended in lysis buffer three times to remove unbound material, and bead-associated proteins were eluted with a buffer comprising 100 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin, and 0.1% NP-40. To assay for association of VKORC1v2 with CatD, expression vectors for VKORC1v2-CBD or CBD fusions of variants 1 and 3 (controls) were cotransfected with a CatD-Flag expression plasmid into HEK293T cultures. Cell lysates (obtained as outlined above) were incubated with chitin beads (catalog number S6651; New England BioLabs) at 4°C overnight. Beads were washed with fresh lysis buffer prior to analysis of bound proteins. For vIL-6-StrepII and VKORC1v2-CBD serial precipitations, StrepTactin beadbound vIL-6-StrepII and associated proteins were eluted in buffer comprising 100 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin, and 0.1% NP-40, and released complexes were then incubated with chitin beads for secondary precipitation of VKORC1v2 complexes. Prior to SDS-PAGE loading, protein samples were boiled in denaturation and reducing buffer (188 mM Tris-HCl [pH 6.8], 3% SDS, 30% glycerol, 10% ␤-mercaptoethanol, and 0.01% bromophenol blue); size fractionation of proteins by SDS-PAGE and electrophoretic transfer to nitrocellulose membranes were carried out using standard procedures. Membranes were blocked in PBS-T buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 , and 0.1% Tween 20) containing 5% nonfat milk prior to the addition of primary antibody (0.1 to 1.0 g/ml) and incubation at 4°C overnight. PBS-T-washed membranes were incubated with horseradish peroxidase-conjugated secondary antibody in PBS-T containing 5% nonfat milk. Membranes were then washed with PBS-T, and membrane-bound antibody was visualized by chemiluminescence assay. Commercially obtained antibodies used for Western analyses were as follows: cathepsin D (catalog number 610800; BD Biosciences), CBD (catalog number E8034S; New England BioLabs), Flag (catalog number F1804; Sigma), GFP (catalog number 1533-1; Epitomics), ␤-actin (catalog number A2228; Sigma), and StrepII (catalog number 3988-100; BioVision). Custom rabbit antiserum to vIL-6 was reported previously by our group (15) .
RESULTS

Identification of cathepsin D as a potential interaction partner of VKORC1v2.
Previous studies from this laboratory identified the importance of VKORC1v2 and its interaction with vIL-6 for maintenance of PEL cell growth and survival (6) . As a first step in identifying the possible mechanism of vIL-6 activity through VKORC1v2, we performed a yeast two-hybrid screen using the ER-lumenal C tail of VKORC1v2 as bait to isolate cDNA clones corresponding to potential cellular interaction partners. Inserts of isolated clones were sequenced to identify the encoded proteins. While many of the sequences corresponded to non-ER proteins likely representing false positives (as are common in such a screen), one of the clones corresponded to the C-terminal region (residues 217 to 412) of cathepsin D (CatD), a predominantly lysosomally localized and occasionally secreted protein processed through the ER. Cathepsin D is produced as a proprotein that is N-terminally and internally cleaved to produce the catalytically active lysosomally localized form, a heterodimer of 34-kDa and 14-kDa CatD fragments (16) . The full-length, catalytically inactive form of CatD (pro-CatD or pCatD) can be secreted and can induce cell proliferation via an unknown mechanism; pCatD has been implicated as a functionally relevant factor in various cancers (16) . While the exact role and mechanisms of action of lysosomally localized and cytoplasmically released mature CatD are incompletely understood, there is substantial evidence linking CatD release from lysosomes with protease-dependent (e.g., via Bid cleavage) and protease-independent (e.g., via Bax activation) induction of apoptosis (17) (18) (19) (20) (21) . Thus, we explored VKORC1v2-CatD interaction in more detail.
The CatD-interacting sequences of VKORC1v2 were mapped using deletion mutagenesis of the ER-localized C-tail region (residues 31 to 92) of VKORC1v2 and yeast two-hybrid analysis. Progressive N-terminal deletions identified the C-terminal 16 residues as sufficient for interaction with CatD in this system (Fig. 1A , top). However, deletion of these sequences in the context of the VKORC1v2 C tail did not abrogate binding, suggesting the presence of another CatD-interacting region (Fig. 1A, middle) . N-terminal deletions were made in sequences lacking the C-terminal 16-amino acid CatD-interacting region, identifying residues 40 to 48 as important for CatD interaction and possibly representing a second CatD-binding domain (Fig. 1A, bottom) . Further experiments were undertaken to test the sufficiency of residues 40 to 48 to bind vIL-6 and to try to map more finely the C-terminal vIL-6-binding residues. The results (Fig. 1B) revealed that residues 40 to 48 (peptide ⌬5-⌬6 [P⌬5-⌬6]) were indeed able to interact with CatD in the yeast two-hybrid assay and that C-terminal residues 77 to 88 (peptide 1, P1) were fully competent for CatD binding. Peptides 2 and 3 (P2 and P3) produced some viable white colonies on conditional medium but were clearly compromised for CatD interaction relative to the ⌬3 (parental) and peptide ⌬5-⌬6 sequences. Thus, these experiments identified residues 40 to 48 and 77 to 88 as independent CatD-interacting regions of VKORC1v2. Notably, these are distinct from the previously mapped vIL-6-binding domain (vBD, residues 31 to 39) of VKORC1v2 (10) .
Verification of VKORC1v2 interaction with cathepsin D. To confirm the interaction between VKORC1v2 and CatD, coimmu-noprecipitation analysis was carried out using epitope-tagged proteins in transfected cells. These analyses included VKORC1 (variant 1), which we have previously reported is inversely orientated in the ER membrane relative to variant 2 and does not bind vIL-6 (10), and VKORC1v3, a novel splice variant of VKORC1 that we identified in PEL cells ( Fig. 2A) . VKORC1v3 lacks residues 58 to 73 of VKORC1 but is otherwise identical. Flag-tagged pCatD was coprecipitated with chitin-binding domain (CBD)-fused VKORC1v2 but not by either of the other two VKORC1 variants (Fig. 2B, left) . This result confirmed the interaction between VKORC1v2 and CatD. Additional coprecipitation experiments for the detection of interactions of the VKORC1 variants with vIL-6 confirmed our previously reported interaction of vIL-6 with variant 2, but not with variant-1, and determined that VKORC1v3 did not bind vIL-6 (Fig. 2B, right) . This result is consistent with identical membrane topologies of variants 1 and 3, placing vIL-6-binding sequences on the cytoplasmic side of the ER membrane (10) .
Additional coprecipitation assays were undertaken to assess the involvement of the C-terminal and vBD-adjacent regions (mapped by yeast two-hybrid analysis) (Fig. 1 ) in pCatD binding. Appropriate singly or dually deleted VKORC1v2 variants were employed (Fig. 2C, top) . StrepII-tagged pCatD was used as the binding partner in this experiment, allowing for improved detection relative to Flag-tagged pCatD. Coprecipitation of pCatD with CBD-fused VKORC1v2 and each VKORC1v2 variant, but not with VKORC1v1-CBD (negative control), was evident. One possible explanation for sustained VKORC1v2-CatD binding despite the deletion of residues 40 to 48 and 77 to 92 (Fig. 2C, ⌬AϩB) , which were mapped as CatD-interacting regions of VKORC1v2 by yeast two-hybrid analysis, is that higher-order complexes are formed in transfected cells that enable indirect association of pCatD and VKORC1v2.
Cooperative binding of vIL-6 and CatD to VKORC1v2. To further examine the nature of CatD-VKORC1v2 interaction and any potential influence of vIL-6, transfection-based VKORC1v2-CatD coprecipitation experiments were performed in the absence or presence of increasing amounts of vIL-6. As before, pCatD coprecipitated by VKORC1v2-CBD was detectable in the absence of vIL-6 coexpression, but amounts of coprecipitated pCatD were Further experiments were undertaken utilizing VKORC1v2 peptide (P)-encoding synthetic oligonucleotides to test the sufficiency of residues 40 to 48 for CatD interaction and to try to map more accurately the C-terminal CatD-interacting region of VKORC1v2. The region comprising amino acids 40 to 48 of VKORC1v2 (P⌬5-⌬6) was able to interact with CatD as effectively as the ⌬5 construction, consisting of residues 40 to 76, used as a positive control. Among the C-terminal peptides, only P1 (comprising residues 77 to 88) was fully competent for CatD interaction.
greatly enhanced, in a dose-dependent manner, with coexpression of vIL-6 (Fig. 3A, left) . Whether vIL-6 binding to VKORC1v2 was required for enhancing the interaction of VKORC1v2 with pCatD was tested by inclusion in a similar experiment of a VKORC1v2 variant lacking residues 31 to 39, which comprise the vIL-6-binding domain (vBD) (10) . The vIL-6-enhanced VKORC1v2-CatD interaction was completely lost when the vBD variant was used in the coprecipitation experiment (Fig. 3A, right) . Deletion of vBD residues also inhibited pCatD interaction with VKORC1v2 in the absence of vIL-6. Taken together, these data indicate that VKORC1v2-CatD interaction is promoted by cointeraction of vIL-6 with VKORC1v2 and that the vBD region itself also positively influences CatD interaction independently of vIL-6.
Additional analysis was undertaken to verify cocomplexing of (Fig. 1) for CatD association using analogous coprecipitation assays employing appropriate single and double deletion variants of VKORC1v2. In this experiment, CatD was tagged with StrepII to facilitate immunoblot detection of the protein in cell lysates. VKORC1v1-expressing plasmid and empty vectors, pSG5.CBD [vec (CBD)] and pSG5 (vector), were used in parallel-transfected cultures to provide negative controls for the experiment. ␣, anti.
VKORC1v2, pCatD, and vIL-6. StrepII-tagged vIL-6 was precipitated with streptavidin (StrepTactin) beads, and coprecipitates were analyzed by immunoblotting for the presence of pCatD, along with the vIL-6-interaction partner VKORC1v2. pCatD coprecipitation was dependent on VKORC1v2 expression and also on vBD integrity (required for vIL-6 binding to VKORC1v2) (Fig.  3B ). In the absence of VKORC1v2, little or no interaction between vIL-6 and pCatD was detected in this or similar experiments. The results indicate that VKORC1v2 forms a platform for vIL-6 and pCatD interactions and that these proteins can cocomplex.
Cocomplexing of vIL-6, VKORC1v2, and CatD was investigated directly using a double-coprecipitation approach. Cells were transfected with vectors expressing vIL-6-StrepII (or an empty vector control), VKORC1v2-CBD, and CatD. Cell lysates from these transfectants were mixed with StrepTactin beads to precipitate StrepII-tagged vIL-6, and then chitin beads were used to isolate VKORC1v2-containing complexes from washed and StrepTactin bead-eluted precipitates. This experiment identified complexes containing all three of these proteins, as evidenced by immunoblot detection of pCatD in double-precipitated material (Fig. 3C) . In this experiment, employing untagged CatD, both full-length pCatD and mature, proteolytically cleaved and lysosomally localized CatD were detected readily in cell lysates, but only pCatD was present in the final precipitates. Thus, interactions of vIL-6 and ER-localized pCatD with VKORC1v2 are coincident and cooperative. ) of vIL-6-encoding plasmid; total transfected DNA was normalized with empty vector plasmid. The detected Flag-specific species migrated just below a 50-kDa marker band (data not shown), consistent with the detected species being the proenzyme form, pCatD (actual size, 52 kDa); the cause of the doublet pattern is unknown but may represent different glycosylation states. The assay was repeated to include a vIL-6-binding domain (vBD)-deleted version of VKORC1v2, VKORC1v2⌬vBD, shown previously to be defective for vIL-6 binding (10); this form was also defective for vIL-6-enhanced VKORC1v2-CatD association (right panels). (B) The possibility of vIL-6, VKORC1v2, and CatD cocomplexing was investigated by coexpression of these proteins in transfected HEK293T cells and StrepTactin bead-mediated precipitation of StrepII-tagged vIL-6 from transfected cell lysates. VKORC1v2-CBD coprecipitation with vIL-6-StrepII was reduced to background levels (vIL-6-negative and vector-only [vec] lanes) by vBD deletion (v2⌬vBD). A Flag-specific band migrating with an apparent molecular mass of ϳ48 kDa and corresponding to pCatD (arrowhead) was detected above background levels only upon coexpression of vIL-6 and VKORC1v2. (C) Cocomplexing was investigated further using a double-precipitation approach, first precipitating vIL-6-StrepII (as before) and then using chitin beads to sediment CBD-fused VKORC1v2 (v2-CBD) from washed primary precipitates. Empty StrepII vector (vec) was used as a negative control. CatD was expressed as a native, untagged protein, leading to readily detectable levels of both full-length pCatD (p) and proteolytically processed, mature (m) CatD in cell lysates. ER-localized pCatD, specifically, was detected in final precipitates from vIL-6-StrepII-expressing lysates. IP, immunoprecipitation.
Influence of vIL-6 on CatD expression in PEL cells.
Having established that pCatD interacts with VKORC1v2 and that vIL-6 both promotes the interaction and cocomplexes with the cellular proteins, we then addressed the possible significance of these interactions. PEL cells were examined because they naturally express vIL-6, which is important for their proliferation and survival (6) . Lentiviral shRNA vector-mediated depletion of vIL-6, which has been used previously for functional analyses of vIL-6 in these cells (6) , was employed to investigate the potential influence of endogenous vIL-6 on CatD expression. In lysates of BCBL-1 and JSC-1 cells, the only form of CatD detected was the fully processed, lysosomally localized form; the 34-kDa subunit of the proteolytically derived dimer composed of 14-kDa and 34-kDa fragments was detectable with the antibody employed for Western blotting (Fig.  4A, left) . In both BCBL-1 and JSC-1 cells, intracellular CatD levels were detectably increased following vIL-6 depletion. RT-PCR analysis of CatD and VKORC1v2 mRNA levels in response to vIL-6 depletion in BCBL-1 cells revealed no detectable effects on these transcripts (Fig. 4A, right) , indicating lack of off-target depletion and likely posttranscriptional regulation of CatD. In the converse of the vIL-6 depletion experiment, overexpression of vIL-6, mediated by lentiviral delivery of a vIL-6 expression cassette (see Materials and Methods) (6) into BCBL-1 and JSC-1 cells, led to reduced levels of CatD (Fig. 4B) .
That vIL-6 interaction with VKORC1v2 was important for vIL-6 effects on CatD expression was determined by introducing ER-directed and ER-retained (signal sequence-and KDEL motiftagged) GFP-fused vBD (vIL-6-binding domain) peptide into PEL cells to disrupt vIL-6 binding to VKORC1v2. This reagent was validated and used previously to determine the relevance of vIL-6 -VKORC1v2 interaction for proproliferative and prosurvival effects of vIL-6 in PEL cells (10) . As before, GFP-vBD-KDEL or GFP-KDEL (control) protein was expressed in BCBL-1 and JSC-1 cells via lentiviral transduction of constitutively active expression cassettes. Western analysis of cell lysates from these cultures revealed that vBD transduction led to increased levels of CatD expression relative to those detected in the control cultures (Fig.  4C) . These data are consistent with a mechanism of vIL-6-mediated suppression of mature CatD via vIL-6-VKORC1v2 interaction-dependent suppression and/or ER-retention of VKORC1v2-interacting pCatD.
This model was examined further in transfected HEK293T cells by using an expression vector (see Materials and Methods) specifying a transcript encoding both native (untagged, efficiently processed) pCatD and mVenus GFP, fused via porcine teschovirus 1 peptide 2A to induce ribosome skipping and thus allow separate but cotranslated expression of the two proteins (13) . This system provided a means of verifying equivalent transfection and expression (of mVenus, and therefore coencoded CatD) between BCBL-1 and JSC-1 PEL cultures were infected with lentiviral vectors constitutively expressing either a nonsilencing (NS, control) shRNA or vIL-6 mRNAdirected shRNA. Cells were harvested 5 days after lentiviral infection. Western blotting was undertaken to measure CatD expression in these cultures and also to verify vIL-6 depletion in vIL-6 shRNA-transduced cells. Blotting for ␤-actin verified equivalent protein loading. The active, 34-kDa chain of mature CatD (lysosomal) was the only form detected, and this was elevated in vIL-6-depleted cells. The experiment was repeated multiple times in BCBL-1 and JSC-1 cultures; representative data are shown. Migration positions of marker bands and their sizes (kDa) are indicated to the right of the JSC-1 CatD blot; the actual size of the detected CatD chain is indicated alongside the BCBL-1 CatD blot. RT-PCR detection of CatD and VKORC1v2 mRNAs in NS and vIL-6 shRNA-transduced BCBL-1 culture lysates revealed no detectable effects of vIL-6 depletion on these cellular mRNA levels (agarose gel sections, right). Unspliced (v1) and spliced (v2) transcripts of VKORC1 are indicated; CatD mRNA primers were designed to amplify across the intron of the variant 2 transcript. (B) Effects of vIL-6 on CatD protein levels were also tested by overexpression, achieved by lentiviral vector-mediated transduction of a vIL-6 expression cassette into BCBL-1 and JSC-1 cells. CatD and vIL-6 levels in cell extracts were detected by Western blotting; immunoblotting for ␤-actin provided a protein normalization control. (C) The relevance of VKORC1v2-vIL-6 interaction for vIL-6-mediated suppression of CatD expression was tested by lentivirus-mediated transduction of vIL-6-binding domain (vBD) sequences of VKORC1v2 fused to signal sequence-and ER retention motif (KDEL)-linked GFP (GFP-vBD.K), which disrupts vIL-6 binding to VKORC1v2 (10) . A lentiviral vector specifying KDEL motif-tagged signal sequence-fused GFP (GFP.K) was used as a negative control. Five days after lentiviral infection, cells were harvested for preparation of cell extracts, and these were analyzed by Western blotting to determine CatD expression levels. Western blotting for GFP and ␤-actin were conducted to confirm transduced protein expression and equivalent protein loading, respectively. (D) CatD suppression by vIL-6 via VKORC1v2 was tested in HEK293T cells. An expression vector encoding GFP (mVenus) and CatD linked by self-cleaving porcine teschovirus peptide 2A (see Materials and Methods) was used to enable coexpression of GFP from the CatD-encoding transcript, enabling verification of equivalent efficiencies of gene transduction in vIL-6 plasmid-and empty vector (vec)-cotransfected cultures. Western blotting of cell lysates prepared 24 h posttransfection was performed utilizing antibodies to CatD, vIL-6, GFP, and ␤-actin (loading control). (E) Immunofluorescence confocal microscopy analysis of CatD subcellular localization in response to vIL-6 coexpression. HEK293T cultures were cotransfected with expression vectors for pCatD and either KDEL motif-fused (ER-directed) GFP (GFP.K) or vIL-6-GFP-KDEL (vIL-6-GFP.K). CatD immunofluorescence signal is red, with GFP-KDEL and vIL-6-GFP-KDEL fluorescing green. Combined (total) and single (slice) z-sections are shown for each condition; each field shown is a representative example of data captured from multiple fields. vIL-6-and empty vector-cotransfected cultures. vIL-6 expression led to the depletion of both ER-localized pCatD and fully processed, lysosomally localized mature CatD (Fig. 4D) . However, expression of mature CatD was suppressed to a greater extent than that of pCatD, indicating that ER exit of pCatD in addition to protein levels is affected by vIL-6. Indeed, immunofluorescence assays provided independent support for vIL-6-mediated ER retention of pCatD as ER-localized CatD (pCatD), visualized by colocalization with KDEL motif-tagged GFP or vIL-6 -GFP, was detectably increased upon coexpression of vIL-6 (Fig. 4E) . Thus, these data indicate that vIL-6 both inhibits ER exit of pCatD and promotes its destabilization, leading to reduced levels of proteolytically cleaved and lysosomally localized mature CatD.
Taken together these findings indicate that vIL-6 may promote PEL cell viability in part through ER-localized and VKORC1v2-mediated suppression of proapoptotic CatD.
Influence of CatD on PEL cell growth and viability. We hypothesized that vIL-6 suppression of CatD would have a positive effect on PEL cell viability, inhibiting predominant proapoptotic activity of mature CatD, but antiapoptotic and progrowth effects of intracellular CatD and secreted pCatD were also possible (16) . To address the potential biological significance of CatD expression in PEL cells, we utilized a lentiviral vector to overexpress CatD in BCBL-1 and JSC-1 cells. Cultures infected with either empty or CatD-expressing lentiviral (lenti-CatD) vectors were allowed to rest for 2 days prior to seeding of cells in fresh medium and monitoring of growth. CatD transduction led to moderate but consistent reductions in cell numbers over time, relative to empty vector-infected cultures (Fig. 5A) . Increased CatD levels in lentiCatD-infected cells were verified by Western blotting of cell lysates on the last day of the experiment (Fig. 5A, bottom) . A similar experiment was conducted, and cells were harvested for detection of apoptosis by annexin V-Cy3 staining after 3 days of growth. The results revealed substantially increased rates of apoptosis in cultures transduced with the lenti-CatD vector relative to those in cultures receiving the empty vector (Fig. 5B) . Together, these experiments demonstrate that CatD expression negatively affects the growth and viability of PEL cells and indicate that regulation of endogenous CatD expression by vIL-6 could potentially be biologically significant.
In contrast to the effects of ectopic CatD expression, however, lentiviral shRNA vector-mediated depletion of endogenous CatD (see Materials and Methods) had no detectable effect on cell growth under normal culture conditions (Fig. 6A) . Effective depletion of CatD was verified by Western blotting of lentivirustransduced cell lysates (Fig. 6A, bottom) . Interestingly, continued incubation of these cell cultures, without a change of medium, revealed that CatD depletion positively affected viable cell numbers, especially for BCBL-1 cultures, and dramatically reduced rates of apoptosis at day 7 (Fig. 6B) . Thus, endogenously expressed CatD can have a profound effect on PEL cell viability under suboptimal growth conditions that induce cell stress. CatD suppression of HHV-8 productive replication. Based on the detected influence of CatD on PEL cell viability under prolonged culture-induced stress, we hypothesized that CatD may be inhibitory to (stress-inducing) HHV-8 productive replication and that vIL-6 might help to counter this activity. To test the influence of endogenous CatD on productive replication, we measured 12-O-tetradecanoylphorbol-13-acetate (TPA) and sodium butyrate (NaB)-induced virus production from BCBL-1 and JSC-1 cultures in the presence and absence of CatD depletion, achieved using the CatD-specific or control (NS) shRNA-encoding lentiviral vectors as before. Following lentiviral infection of PEL cultures to introduce either CatD shRNA or NS shRNA expression cassettes, cells were incubated for 2 days, normalized for cell number, and then treated with TPA/NaB (see Materials and Methods) to induce lytic replication. Titers of released virus from these cultures were measured by latency-associated nuclear antigen (LANA) immunostaining of naive TIME cell cultures inoculated with harvested PEL culture medium. Virus production in CatD-depleted BCBL-1 and JSC-1 cells was substantially increased (between 2-and 3-fold) relative to NS shRNA-transduced cultures (Fig. 7A) , revealing the inhibitory effects of endogenous CatD on virus replication. In a similar experiment, CatD depletion led to reductions in lytic cycle-induced apoptosis in TPA/NaB-treated cultures (Fig. 7B) , reflecting the results observed following stress induced by prolonged incubation of PEL cells in unchanged growth medium (Fig. 6B) . Conversely, overexpression of CatD by appropriate lentiviral vector infection of BCBL-1 and JSC-1 cells led to decreased virus production (Fig. 7C ) and increased apoptosis (Fig. 7D) in TPA/ NaB-induced cultures. Further, control experiments were undertaken to verify that CatD suppression or overexpression in the absence of TPA/NaB did not induce lytic replication (Fig.  7E) . These experiments confirmed that CatD expression affects lytic replication once it is in progress, not the initiation of productive replication. Combined, the data from the replication experiments indicate that CatD negatively influences HHV-8 productive replication via its proapoptotic activity.
Promotion of HHV-8 replication via vIL-6-VKORC1v2 interaction. The replication results from the CatD depletion and overexpression experiments (Fig. 7) together with the observed suppressive effects of vIL-6 on CatD expression (Fig. 4) suggested that vIL-6 might enhance HHV-8 productive replication by acting through VKORC1v2 to diminish the proapoptotic effects of CatD. To test the influence of vIL-6 on replication, HHV-8 production from TPA/NaB-treated BCBL-1 and JSC-1 cultures was measured in response to vIL-6 depletion. As undertaken previously in this laboratory (6), vIL-6 depletion was mediated by (GFP ϩ ) lentiviral vector-mediated introduction of vIL-6-specific shRNA. NS shRNAencoding lentivirus was used as a control. Equivalently infected and cell density-normalized PEL cultures were treated with TPA for 3 (JSC-1) or 5 (BCBL-1) days, and medium was harvested for virus titration. As hypothesized, virus production from vIL-6 shRNA-transduced cultures was diminished relative to that of NS shRNA-transduced controls (Fig. 8A) . As a control for potential off-target effects of vIL-6 shRNA, a similar experiment was undertaken in JSC-1 cultures and shRNA-resistant vIL-6 was introduced via lentiviral transduction (6) to rescue the vIL-6 depletion phenotype; the negative effects of vIL-6 shRNA transduction on HHV-8 productive replication could be reversed by vIL-6 supplementation (Fig. 8B ). These data demonstrate a positive influence of vIL-6 on HHV-8 productive replication in PEL cells, an effect potentially mediated, in whole or in part, via vIL-6 -VKORC1v2 association and CatD suppression.
To test the relevance of vIL-6-VKORC1v2 interaction for vIL-6-enhanced productive replication in BCBL-1 and JSC-1 cells, shRNA or vIL-6-specific lentivirus-encoded shRNAs, as reported previously (6) . These cultures were allowed to rest for 2 days and were then treated with TPA/NaB to induce lytic replication. GFP-vBD-KDEL (vIL-6 -VKORC1v2 interaction-disrupting [10] ) or GFP-KDEL (control) protein was introduced into these cells using lentiviral vectors (as outlined above). Introduction of GFPvBD-KDEL into each of the PEL cell types led to substantial diminution of released infectious virus titers relative to those produced from GFP-KDEL-transduced cultures (Fig. 8C and D) . Furthermore, rates of apoptosis in these cultures were substantially increased by vBD transduction, as determined by annexin V-Cy3 staining of cells at the time of medium harvest. These data indicate that vIL-6 interactions with VKORC1v2 contribute significantly to the proreplication effects of vIL-6 and suggest that vIL-6 -VKORC1v2 interaction-dependent suppression of CatD is a likely mechanism through which this activity is mediated.
To test directly the influence of vIL-6 and vIL-6-VKORC1v2 interaction on endogenous CatD expression during productive replication, vIL-6 shRNA-or vBD-transduced JSC-1 cultures were analyzed for CatD levels at 2 days postinduction of lytic replication with TPA/NaB. Immunoblotting of cell lysates from these and control (NS shRNA-and GFP-KDEL-transduced) cultures revealed that mature CatD (the only form detected) was expressed at higher levels in vIL-6-depleted cells and suppressed in vBDtransduced cells (Fig. 9A) . These data are consistent with the hypothesis that vIL-6 enhances replication at least in part via CatD suppression. The link between vIL-6 and CatD in relation to proreplication activity of vIL-6 was further investigated functionally by single and codepletion of vIL-6 and/or CatD. JSC-1 cultures were transduced using dose-normalized lentiviral vector infection with NS, vIL-6, CatD, or vIL-6 plus CatD shRNA, followed by TPA/NaB induction of productive replication. Measurements of infectious virus yields revealed that while vIL-6 depletion led to reduced HHV-8 titers, as before, the effect of vIL-6 depletion could be abrogated by CatD codepletion (Fig. 9B) . These data indicate a functional relationship between vIL-6 suppression of CatD and proreplication activity of the viral cytokine.
DISCUSSION
While the mechanisms of vIL-6 activity via the gp130 signal transducer both at the cell surface and from the ER is well established (6, 8, (22) (23) (24) , the mechanism by which vIL-6 supports PEL cell growth via VKORC1v2 has not previously been investigated. Here, we have identified the CatD proenzyme (pCatD) as an interaction partner of VKORC1v2 and determined that vIL-6 can cocomplex with pCatD and VKORC1v2 and promote the interaction between the two cellular proteins. Further, vIL-6 leads to suppression of CatD expression both in PEL cells naturally expressing CatD and vIL-6 and in reconstituted transfected cells. Functionally, CatD depletion, vIL-6 expression, and vIL-6 -VKORC1v2 association (required for CatD suppression) all promote cell viability under stress conditions and support HHV-8 productive replication; CatD overexpression has the opposite effects. Therefore, these findings reveal a mechanism contributing to the previously reported ER-localized vIL-6 antiapoptotic activity (6, 10) and also extend understanding of CatD intracellular interactions and activity.
It is well established that CatD can function to promote apoptosis; however, the precise mechanisms involved are incompletely understood. One mechanism appears to involve CatD-mediated mitochondrial activation and localization of Bax, as demonstrated in staurosporine-treated T cells (20) . Enhanced tumor necrosis factor (TNF)-induced apoptosis in CatD-null fibroblasts expressing ectopic CatD suggests that CatD may target the BH3-only protein Bid for cleavage (activation) and thereby promote apoptosis (18) . This process is dependent on ceramide, a mediator of apoptosis induced by cytokines, starvation, radiation, and other stimuli; ceramide promotes CatD maturation and endosome-tocytosolic translocation. CatD may induce apoptosis independently of its protease activity, as apoptosis induced by ectopically expressed CatD can be resistant to the CatD inhibitor pepstatin A and as catalytically inactive (unprocessed or mutated) CatD can induce apoptosis as well as mature wild-type CatD in various cell types (19, 25) . Contrasting with the various reports of CatD proapoptotic activity, prosurvival effects of exogenous CatD in the context of tumor xenograft apoptosis have been reported, and similar activities of wild-type or catalytically inactive CatD were found in transfected fibroblasts deficient in endogenous CatD (26, The functional relevance of CatD modulation to vIL-6 function was tested by single and dual depletion of vIL-6 and/or CatD in JSC-1 cells, followed by TPA/NaBinduced reactivation of lytic replication and, after 3 days, by assays of released infectious virus titers. Percentages of LANA ϩ (infected) cells in inoculated naive TIME cell cultures were calculated for nine random fields to determine relative virus titers derived from each PEL culture. Average values are shown; error bars indicate single-field deviations from mean percent LANA ϩ cell values. 27 ). In addition to apoptotic regulation by CatD, it is notable that the full-length, unprocessed proprotein is able to induce cell proliferation following extracellular secretion. Indeed, overexpression and secretion of pCatD have been observed in many tumors and cancer cell lines and have been proposed to be significant contributors to disease (28) (29) (30) (31) . The ␤-chain of low-density lipoprotein (LDL) receptor-related protein 1 (LRP1␤) has been reported to bind pCatD and to direct the ligand to lipid rafts. Signal transduction could conceivably involve CatD-induced LRP1␤ tyrosine phosphorylation or ␤-chain hydrolysis, leading to downstream regulation of gene expression (32) . Thus, in addition to apoptotic regulation mediated by processed, intracellular CatD via mechanisms dependent on and independent of CatD protease activity, the catalytically inactive proenzyme is able to affect mitogenic signaling at the cell surface. The extent of functionally important interaction partners of CatD in each of these processes remains to be determined. To our knowledge, our studies are the first to identify an ER-localized CatD interaction partner, VKORC1v2. We have found not only that this interaction is relevant to overall CatD expression regulated by vIL-6 in PEL cells but also that such regulation is biologically significant with respect to PEL cell survival and to virus productive replication. The role of VKORC1v2-pCatD interaction in uninfected cells and the identity of cellular proteins that may cocomplex with VKORC1v2 and pCatD within the ER compartment are important topics for future investigation. The mechanism of CatD suppression via cointeraction of vIL-6 and pCatD with VKORC1v2 is presently being investigated, and this may shed light on the biological significance of VKORC1v2-pCatD interaction in normal cell biology.
A notable finding from this study is that vIL-6 promotes HHV-8 productive replication in the PEL cell lines examined, at least in part through VKORC1v2 and likely via CatD regulation. A previous study by Chen and Lagunoff (9) tested the replication competence of a vIL-6-null HHV-8 mutant virus against that of wild-type virus in the context of lytic reactivation from latently infected BJAB cells. These studies detected no difference in the replication efficiencies of the native and mutated viruses. It seems, therefore, that the role of vIL-6 in replication is cell type dependent, as is the case for vIL-6-mediated progrowth and prosurvival activities. Evidence for the involvement of VKORC1v2 and CatD in vIL-6 proreplication activity in PEL cells includes the observed inhibition of replication by VKORC1v2-vIL-6 interaction-disrupting vBD peptide transduction, reduction and enhancement of CatD expression in lytically reactivated PEL cells by vIL-6 overexpression and depletion, respectively, and the abrogation of vIL-6 depletion-mediated inhibition of productive replication by CatD codepletion. However, while our studies identify the involvement of VKORC1v2-vIL-6 interaction in proreplication activity of the viral cytokine and indicate that this may be mediated through CatD suppression, we do not exclude the possibility that vIL-6 may act also via other mechanisms, including gp130 signal transduction, to mediate this function. Additional research to address this issue is warranted and will further elucidate the biological roles of vIL-6.
In summary, the present studies have identified CatD as a new interaction partner of vIL-6-targeted VKORC1v2, determined that vIL-6 regulates CatD expression levels in PEL cells via interaction with VKORC1v2, and established that vIL-6 -VKORC1v2 interaction and the regulation of CatD levels are important for PEL cell viability during latent and lytic infection and for virus productive replication. These data further our understanding of vIL-6 function and its mechanisms of activity in PEL cells and virus biology and also reveal a previously unknown, ER-localized interaction of CatD. Further dissection of the molecular basis and biological consequences of vIL-6 and CatD interactions with VKORC1v2 and the related mechanisms underlying regulation of CatD expression is in progress and has the potential to lead to the development of novel therapeutic approaches for PEL.
